The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

BACKGROUND: Although pembrolizumab has shown clinical benefit in patients with small-cell lung cancer (SCLC), its actual efficacy in combination with a conventional chemotherapy drug has not been determined. We performed this study to discern the efficacy and risk of pembrolizumab in combination wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiangyun, Zhang, Yixuan, Liu, Miaowen, Xu, Ruoxin, Yi, Fengming, Wei, Yiping, Zhu, Shuqiang, Zhang, Wenxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515717/
https://www.ncbi.nlm.nih.gov/pubmed/34645484
http://dx.doi.org/10.1186/s12957-021-02410-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515717/
https://www.ncbi.nlm.nih.gov/pubmed/34645484
http://dx.doi.org/10.1186/s12957-021-02410-3

Ejemplares similares